FDA approves Livmarli oral tablets for PFIC, Alagille
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…
Severe mutations in the ABCB11 gene cause progressive familial intrahepatic cholestasis type 2 (PFIC2) by destabilizing the resulting BSEP protein in a specific region,…
Analyzing the presence of different proteins in liver tissue under a microscope can be used to help diagnose progressive familial intrahepatic cholestasis (PFIC) and…
Livmarli (maralixibat) has been approved in Japan for the treatment of itching in people with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC),…
A new mutation in the ABCB4 gene was found to cause progressive familial intrahepatic cholestasis (PFIC) type 3 in a young woman, a case…
I have a confession to make: I’ve been a bad advocate for progressive familial intrahepatic cholestasis (PFIC). OK, maybe I haven’t been a bad…
A young woman in the U.S. who experienced recurrent cholestasis was later found, with the help of genetic testing, to have a mutation in…
Intrahepatic cholestasis of pregnancy (ICP) is estimated to affect nearly 3% of pregnant women worldwide, with the highest incidence reported in Asia and the…
Researchers have developed a tool that can distinguish medications that result in cholestasis from those that don’t, based on their effects on key bile…
The ripples of progressive familial intrahepatic cholestasis (PFIC) continue to spread throughout our family, as branches of the family tree are tested to see…